Federal Challenge Set to Review Impact of Medicare Drug Price Rules on Pharmaceutical Stability
In a significant development, the federal government has requested the full D.C. Circuit to review a decision regarding Teva Pharmaceuticals’ ability to contest Medicare’s drug pricing rules. This appeal follows a panel ruling permitting Teva to challenge the criteria Medicare employs to determine which drugs are eligible for price negotiations. The government argues that this…